Kan Yonemori

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 61

Top Topics

Epidermal Growth Factor Receptor

Top Venues

Nature medicine

Journal of gynecologic oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Chiharu Mizoguchi, Tadaaki Nishikawa, Hiroshi Yoshida, Masanori Yasuda, Tomoyasu Kato, Kosei Hasegawa, Kan Yonemori
HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma. Journal of gynecologic oncology (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Hiroshi Ikeuchi, Yusuke Matsuno, Rika Kusumoto-Matsuo, Shinya Kojima, Toshihide Ueno, Masachika Ikegami, Rina Kitada, Hitomi Sumiyoshi-Okuma, Yuki Kojima, Kan Yonemori, Yasushi Yatabe, Kazuya Takamochi, Kenji Suzuki, Ken-Ichi Yoshioka, Hiroyuki Mano, Shinji Kohsaka
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway. Oncogene (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Rui Kitadai, Tatsunori Shimoi, Shu Yazaki, Hitomi Sumiyoshi Okuma, Mai Hoshino, Munehiro Ito, Ayumi Saito, Shosuke Kita, Yuki Kojima, Tadaaki Nishikawa, Kazuki Sudo, Emi Noguchi, Yasuhiro Fujiwara, Masayuki Yoshida, Kan Yonemori
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast cancer (Tokyo, Japan) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Risako Ozawa, Tadaaki Nishikawa, Hiroshi Yoshida, Kouya Shiraishi, Tatsunori Shimoi, Tomoyasu Kato, Kan Yonemori
Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers. Journal of gynecologic oncology (2024)
Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, Mayu Yunokawa, Kimio Ushijma, Shiro Suzuki, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Jae-Weon Kim, Byoung Gie Kim, Peng-Hui Wang, Ting-Chang Chang, Keiko Yamamoto, Shirong Han, Jodi-Ann Mckenzie, Robert J Orlowski, Takuma Miura, Vicky Makker, Yong Man Kim
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Journal of gynecologic oncology 35 (2) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. NPJ breast cancer 10 (1) (2024)
Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, Mayu Yunokawa, Kimio Ushijma, Shiro Suzuki, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Jae-Weon Kim, Byoung Gie Kim, Peng-Hui Wang, Ting-Chang Chang, Keiko Yamamoto, Shirong Han, Jodi-Ann Mckenzie, Robert J Orlowski, Takuma Miura, Vicky Makker, Yong Man Kim
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Journal of gynecologic oncology 35 (2) (2024)
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, Ryoko Seki, Noboru Yamamoto
Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors. Cancer research communications (2024)
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. NPJ breast cancer 10 (1) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Tadaaki Nishikawa, Shigeki Kakunaga, Kenji Tamura, Masashi Ando, Toshiyoshi Fujiwara, Akira Kawai, Takafumi Ueda, Mamiko Kawasaki, Sawako Tomatsuri, Nobuko Okamura, Masahisa Kamikura, Akinobu Hamada, Akihiko Yoshida, Akihiro Hirakawa, Taro Shibata, Kenichi Nakamura, Kan Yonemori
Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510). Cancer (2024)
Hiroshi Ikeuchi, Yusuke Matsuno, Rika Kusumoto-Matsuo, Shinya Kojima, Toshihide Ueno, Masachika Ikegami, Rina Kitada, Hitomi Sumiyoshi-Okuma, Yuki Kojima, Kan Yonemori, Yasushi Yatabe, Kazuya Takamochi, Kenji Suzuki, Ken-Ichi Yoshioka, Hiroyuki Mano, Shinji Kohsaka
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway. Oncogene (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. NPJ breast cancer 10 (1) (2024)
Hiroshi Ikeuchi, Yusuke Matsuno, Rika Kusumoto-Matsuo, Shinya Kojima, Toshihide Ueno, Masachika Ikegami, Rina Kitada, Hitomi Sumiyoshi-Okuma, Yuki Kojima, Kan Yonemori, Yasushi Yatabe, Kazuya Takamochi, Kenji Suzuki, Ken-Ichi Yoshioka, Hiroyuki Mano, Shinji Kohsaka
Correction: GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway. Oncogene (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, Mayu Yunokawa, Kimio Ushijma, Shiro Suzuki, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Jae-Weon Kim, Byoung Gie Kim, Peng-Hui Wang, Ting-Chang Chang, Keiko Yamamoto, Shirong Han, Jodi-Ann Mckenzie, Robert J Orlowski, Takuma Miura, Vicky Makker, Yong Man Kim
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Journal of gynecologic oncology 35 (2) (2024)
Komal L Jhaveri, Elgene Lim, Rinath M Jeselsohn, Cynthia X Ma, Erika Paige Hamilton, Cynthia Osborne, Manali Bhave, Peter A Kaufman, J Thaddeus Beck, Luis Manso Sanchez, Ritesh Parajuli, Hwei-Chung Wang, Jessica J Tao, Seock-Ah Im, Kathleen K Harnden, Kan Yonemori, Ajay Dhakal, Patrick Neven, Philippe Aftimos, Jean-Yves Pierga, Yen-Shen Lu, Timothy Larson, Yolanda Jerez, Kostandinos Sideras, Joo Hyuk Sohn, Sung-Bae Kim, Cristina Saura, Aditya Bardia, Sarah L Sammons, Francesca Bacchion, Yujia Li, Eunice Yuen, Shawn T Estrem, Vanessa Rodrik-Outmezguine, Bastien Nguyen, Roohi Ismail-Khan, Lillian M Smyth, Muralidhar Beeram
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, Mayu Yunokawa, Kimio Ushijma, Shiro Suzuki, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Jae-Weon Kim, Byoung Gie Kim, Peng-Hui Wang, Ting-Chang Chang, Keiko Yamamoto, Shirong Han, Jodi-Ann Mckenzie, Robert J Orlowski, Takuma Miura, Vicky Makker, Yong Man Kim
Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Journal of gynecologic oncology (2024)
Shigehiro Yagishita, Tadaaki Nishikawa, Hiroshi Yoshida, Daisuke Shintani, Sho Sato, Maiko Miwa, Mikiko Suzuki, Masanori Yasuda, Yusuke Ogitani, Takahiro Jikoh, Kan Yonemori, Kosei Hasegawa, Akinobu Hamada
Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Hitomi Sumiyoshi Okuma, Keisuke Watanabe, Kenji Tsuchihashi, Ryunosuke Machida, Ryo Sadachi, Akihiro Hirakawa, Hiroshi Ariyama, Masashi Kanai, Masahisa Kamikura, Kenta Anjo, Akari Hiramitsu, Shigeki Sekine, Natsuko Okita, Hiroyuki Mano, Hiroyoshi Nishikawa, Kenichi Nakamura, Kan Yonemori
Phase 2 trial of nivolumab in metastatic rare cancer with dMMR or MSI-H and relation with immune phenotypic analysis (the ROCK trial). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Tadaaki Nishikawa, Kosei Hasegawa, Koji Matsumoto, Masahiko Mori, Yasuyuki Hirashima, Kazuhiro Takehara, Kazuya Ariyoshi, Tomoyasu Kato, Shigehiro Yagishita, Akinobu Hamada, Mamiko Kawasaki, Satoshi Kawashima, Sawako Tomatsuri, Yukari Nagasaka, Hiroshi Yoshida, Ryunosuke Machida, Akihiro Hirakawa, Kenichi Nakamura, Kan Yonemori
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, Bradley J Monk, Helen Mackay, Alessandro D Santin, David Scott Miller, Richard G Moore, Sally Baron-Hay, Isabelle L Ray-Coquard, Kimio Ushijma, Kan Yonemori, Yong Man Kim, Eva M Guerra Alia, Ulus A Sanli, Steven Bird, Robert Orlowski, Jodi-Ann Mckenzie, Chinyere E Okpara, Gianmaria Barresi, Domenica Lorusso
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Kohei Shitara, Motohiro Hirao, Satoru Iwasa, Takashi Oshima, Yoshito Komatsu, Akihito Kawazoe, Yasuyoshi Sato, Takuya Hamakawa, Kan Yonemori, Nozomu Machida, Satoshi Yuki, Takuya Suzuki, Shiori Okumura, Takao Takase, Taro Semba, Bob Zimmermann, Angela Teng, Kensei Yamaguchi
Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF): Results From the Advanced Gastric Cancer Expansion Cohort. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Takafumi Koyama, Toshio Shimizu, Yuki Kojima, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Tatsunori Shimoi, Hitotshi Ichikawa, Shinji Kohsaka, Ryo Sadachi, Akihiro Hirakawa, Akihiko Yoshida, Reiko Makihara Ando, Toshihide Ueno, Mitsuru Yanagaki, Naoko Matsui, Kenichi Nakamura, Noboru Yamamoto, Kan Yonemori
Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study. Cancer discovery (2023)
Ian E Krop, Norikazu Masuda, Toru Mukohara, Shunji Takahashi, Takahiro Nakayama, Kenichi Inoue, Hiroji Iwata, Yutaka Yamamoto, Ricardo H Alvarez, Tatsuya Toyama, Masato Takahashi, Akihiko Osaki, Shigehira Saji, Yasuaki Sagara, Joyce O'Shaughnessy, Shoichi Ohwada, Kumiko Koyama, Tatsuya Inoue, Li Li, Parul Patel, Joseph Mostillo, Yoshimi Tanaka, David W Sternberg, Dalila Sellami, Kan Yonemori
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hitomi Sumiyoshi Okuma, Hiroshi Yoshida, Yoshihisa Kobayashi, Motoko Arakaki, Chiharu Mizoguchi, Lina Inagaki, Voon Pei Jye, Adam Malik Bin Ismail, Hwoei Fen Soo Hoo, Suhana Yusak, Marcelo Severino B Imasa, Thinh Nguyen Huy, Tu Thai Anh, Shinji Kohsaka, Hiroyuki Mano, Kan Yonemori, Kenichi Nakamura, Yasushi Yatabe
Molecular pathology quality control in Southeast Asia: Results of a Multiregional Quality Assurance Study from MASTER KEY Asia. Cancer science (2023)
Rui Kitadai, Tadaaki Nishikawa, Hiroshi Yoshida, Chiharu Mizoguchi, Kasumi Yamamoto, Tomoyasu Kato, Kan Yonemori
Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression. Journal of gynecologic oncology (2023)
Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, Shunsuke Kondo, Kan Yonemori, Kohei Shitara, Satoshi Shiono, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Takuya Suzuki, Takao Takase, Shuya Takashima, Kohei Yamaguchi, Taro Semba, Noboru Yamamoto
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. Cancer research communications 3 (7) (2023)
Tadaaki Nishikawa, Kosei Hasegawa, Koji Matsumoto, Masahiko Mori, Yasuyuki Hirashima, Kazuhiro Takehara, Kazuya Ariyoshi, Tomoyasu Kato, Shigehiro Yagishita, Akinobu Hamada, Mamiko Kawasaki, Satoshi Kawashima, Sawako Tomatsuri, Yukari Nagasaka, Hiroshi Yoshida, Ryunosuke Machida, Akihiro Hirakawa, Kenichi Nakamura, Kan Yonemori
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Kuniko Sunami, Takashi Kubo, Kazuki Sudo, Kayoko Tao, Makoto Hirata, Kan Yonemori, Ken Kato, Takuji Okusaka, Yuichiro Ohe, Yoshiyuki Matsui, Naoya Yamazaki, Chitose Ogawa, Akira Kawai, Yoshitaka Narita, Minoru Esaki, Noboru Yamamoto
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer science (2022)
Shin Nishio, Kan Yonemori, Tomoka Usami, Shinichiro Minobe, Mayu Yunokawa, Takashi Iwata, Aikou Okamoto, Yoichi Aoki, Hiroaki Itamochi, Munetaka Takekuma, Kenichi Harano, Keiko Yamamoto, Takeshi Maruko, Hiroyuki Ugai, Cumhur Tekin, Nicoletta Colombo, Keiichi Fujiwara, Kosei Hasegawa, Kimio Ushijima
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826. Cancer science 113 (11) (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Kan Yonemori, Mayu Yunokawa, Kimio Ushijima, Jun Sakata, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Takayuki Enomoto, Kazuhiro Takehara, Kosei Hasegawa, Wataru Yamagami, Keiko Yamamoto, Shirong Han, Lea Dutta, Robert Orlowski, Takuma Miura, Vicky Makker, Keiichi Fujiwara
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. Cancer science 113 (10) (2022)
Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Shigemasa Takamizawa, Rui Kitadai, Tadaaki Nishikawa, Tatsunori Shimoi, Kazuki Sudo, Ayumi Saito, Hitomi Sumiyoshi Okuma, Maki Tanioka, Emi Noguchi, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato, Yasuhiro Fujiwara, Yuichiro Ohe, Kan Yonemori
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. Journal of gynecologic oncology 33 (6) (2022)
Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (9) (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, Fumiharu Yokoyama, Hiroyuki Iida, Maki Kondo, Noboru Yamamoto
First-in-human study of ONO-4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors. Cancer science (2022)
Kan Yonemori, Yasutoshi Kuboki, Kosei Hasegawa, Takashi Iwata, Hidenori Kato, Kazuhiro Takehara, Yasuyuki Hirashima, Hisamori Kato, Chaitali Passey, Jeppe Klint Buchbjerg, Jeffrey R Harris, Camilla Mondrup Andreassen, Leonardo Nicacio, Ibrahima Soumaoro, Keiichi Fujiwara
Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study. Cancer science 113 (8) (2022)
Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (14) (2021)
Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V Faller, Lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-Pyo Kim
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Targeted oncology (2021)
Keiichi Fujiwara, Hiroyuki Fujiwara, Hiroyuki Yoshida, Toyomi Satoh, Kan Yonemori, Shoji Nagao, Takashi Matsumoto, Hiroaki Kobayashi, Hughes Bourgeois, Philipp Harter, Anna Maria Mosconi, Isabel Palacio Vazquez, Reinthaller Alexander, Tomoko Fujita, Philip Rowe, Eric Pujade-Lauraine, Isabelle L Ray-Coquard
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. Journal of gynecologic oncology 32 (5) (2021)
Nobuhiko Hasegawa, Shinji Kohsaka, Kana Kurokawa, Yuki Shinno, Ikuko Takeda Nakamura, Toshihide Ueno, Shinya Kojima, Masahito Kawazu, Yoshiyuki Suehara, Muneaki Ishijima, Yasushi Goto, Yuki Kojima, Kan Yonemori, Takuo Hayashi, Tsuyoshi Saito, Takehito Shukuya, Fumiyuki Takahashi, Kazuhisa Takahashi, Hiroyuki Mano
Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers. Cancer science 112 (10) (2021)
Tatsunori Shimoi, Emi Noguchi, Kazuki Sudo, Yu Jo Chua, Kan Yonemori
Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (31) (2021)
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Kan Yonemori, Kenji Tamura, Kosei Hasegawa, Akinobu Hamada
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (14) (2021)
Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai, Sakuragi Noriaki, Hidemichi Watari, Nobutaka Takahashi, Hidenori Kato, Kosei Hasegawa, Kan Yonemori, Mika Mizuno, Kazuhiro Takehara, Hitoshi Niikura, Takashi Sawasaki, Sari Nakao, Toshiaki Saito, Takayuki Enomoto, Satoru Nagase, Nao Suzuki, Takashi Matsumoto, Asumi Okumura, Kenzo Sonoda, Satomi Aihara, Yoichi Aoki, Aikou Okamoto, Hirokuni Takano, Hiroshi Kobayashi, Hisamori Kato, Yoshito Terai, Akira Takazawa, Yusuke Takahashi, Yoshinobu Namba, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama, Ikuo Konishi
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (33) (2021)
Shunsuke Kondo, Toshio Shimizu, Takafumi Koyama, Jun Sato, Satoru Iwasa, Kan Yonemori, Yutaka Fujiwara, Akihiko Shimomura, Shigehisa Kitano, Kenji Tamura, Noboru Yamamoto
First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer science 112 (4) (2021)